Drug Development Pipeline
Restore CFTR Function
Eluforsen (QR-010) is an oligonucleotide designed to repair CFTR-encoded mRNA, which could result in a normal CFTR protein in people who have one or two copies of the F508del mutation. It is delivered via inhalation.
A phase 1 proof of concept study to evaluate the effect of eluforsen on nasal CFTR function was completed in 2016. A phase 1b trial to assess the safety and tolerability of eluforsen was completed in 2017.
No further clinical development in CF is planned at this time.
This program is sponsored by ProQR Therapeutics and partially funded by the Cystic Fibrosis Foundation. It is being conducted within the Therapeutics Development Network.
Recent Eluforsen (QR-010) Studies
Closed to Enrollment
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More